169 related articles for article (PubMed ID: 35585821)
1. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
3. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
Wang L; Yang X; Zhou F; Sun X; Li S
Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
[TBL] [Abstract][Full Text] [Related]
4. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
6. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation Sequencing Analysis of mRNA Profile in Cisplatin-Resistant Gastric Cancer Cell Line SGC7901.
Deng Z; Wang H; Guo G; Li X; Cai Y; Tang Y; Wang Y; Li J; Lu Z; Yu X; Li R; Li L
Med Sci Monit; 2019 Apr; 25():2386-2396. PubMed ID: 30938333
[TBL] [Abstract][Full Text] [Related]
8. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
[TBL] [Abstract][Full Text] [Related]
10. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
[TBL] [Abstract][Full Text] [Related]
11. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
12. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
[TBL] [Abstract][Full Text] [Related]
13. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway.
Wei S; Zhang Y; Ma X; Yao Y; Zhou Q; Zhang W; Zhou C; Zhuang J
Sci Rep; 2023 Jul; 13(1):12351. PubMed ID: 37524857
[TBL] [Abstract][Full Text] [Related]
14. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencing.
Wang Y; Liu L; Chen Z
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2820-2829. PubMed ID: 31293179
[TBL] [Abstract][Full Text] [Related]
17. Sericin inhibits MDA‑MB‑468 cell proliferation via the PI3K/Akt pathway in triple‑negative breast cancer.
Niu L; Yang S; Zhao X; Liu X; Si L; Wei M; Liu L; Cheng L; Qiao Y; Chen Z
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313947
[TBL] [Abstract][Full Text] [Related]
18. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation.
Li Y; Wang Z; Yang J; Sun Y; He Y; Wang Y; Chen X; Liang Y; Zhang N; Wang X; Zhao W; Hu G; Yang Q
Mol Cancer; 2024 May; 23(1):102. PubMed ID: 38755678
[TBL] [Abstract][Full Text] [Related]
19. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Kwok CW; Treeck O; Buchholz S; Seitz S; Ortmann O; Engel JB
Target Oncol; 2015 Sep; 10(3):365-73. PubMed ID: 25293576
[TBL] [Abstract][Full Text] [Related]
20. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
